GPR40 Modulating Compounds for Insulin Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively treating or preventing conditions such as type II diabetes, obesity, and related metabolic disorders, as they do not adequately modulate insulin levels or address the underlying physiological mechanisms involving G-protein-coupled receptor GPR40.
Innovation Solution
Development of compounds that modulate GPR40 function, specifically activating or inhibiting it to regulate insulin secretion and metabolism, thereby treating or preventing conditions like type II diabetes, obesity, and other metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat metabolic disorders, then treatment is provided, but insulin levels are not adequately regulated and underlying physiological mechanisms are not addressed
Solution Approach 1:
The patent modifies the molecular structure of GPR40 ligands by changing chemical parameters (introducing specific functional groups, modifying molecular weight, adjusting lipophilicity) to create compounds that effectively modulate GPR40 receptor activity, thereby regulating insulin secretion and addressing metabolic disorders more effectively than current therapies
Solution Approach 2:
The patent introduces GPR40 modulating compounds as intermediary substances that mediate between dietary fatty acids and insulin secretion. These compounds bind to GPR40 receptors on pancreatic beta cells, triggering controlled insulin release and serving as a therapeutic intermediary to regulate blood glucose and lipid metabolism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively regulate insulin levels and treat or prevent metabolic disorders by modulating GPR40, providing a therapeutic approach to manage conditions such as type II diabetes, obesity, and related metabolic issues.
Implementation Method 1
GPR40 is a member of the gene superfamily of G-protein coupled receptors (GPCRs). GPCRs are membrane proteins characterized as having seven putative transmembrane domains that respond to a variety of molecules by activating intra-cellular signaling pathways critical to a diversity of physiological functions.
Implementation Method 2
GPR40 activation is linked to modulation of the Gq family of intra-cellular signaling proteins and concomitant induction of elevated calcium levels.
Data Source
AI summary
The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formulaQ-L1-P-L2-M-X-L3-Awherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.